Jointown(600998)
Search documents
九州通(600998) - 2023 Q4 - 年度财报
2024-04-26 09:31
Financial Performance - Company's operating revenue reached a historical high of 150.14 billion yuan, a year-on-year increase of 6.92%[2] - Non-GAAP net profit attributable to the parent company was 1.96 billion yuan, a year-on-year increase of 13.06%[2] - Operating cash flow reached a record high of 4.748 billion yuan, a year-on-year increase of 19.10%[2] - Revenue for 2023 reached 150.14 billion RMB, a 6.92% increase compared to 2022[27] - Net profit attributable to shareholders in 2023 was 2.17 billion RMB, up 4.27% year-over-year[27] - Operating cash flow increased by 19.10% to 4.75 billion RMB in 2023[27] - Total assets grew by 0.52% to 92.79 billion RMB at the end of 2023[27] - Basic earnings per share rose 7.84% to 0.55 RMB in 2023[28] - Weighted average return on equity (ROE) increased by 0.06 percentage points to 9.04% in 2023[28] - The company achieved operating revenue of 150.14 billion yuan, a year-on-year increase of 6.92%, and net profit attributable to the parent company of 2.174 billion yuan, a year-on-year increase of 4.27%[172] - The company's main business revenue reached 149.981 billion yuan, a year-on-year increase of 6.91%, with a gross profit of 12.049 billion yuan, a year-on-year increase of 10.48%[173] Business Segments and Revenue Growth - The company's pharmaceutical industry self-produced and OEM business sales revenue reached 2.476 billion yuan[4] - The company's total agency brand promotion business (CSO) sales revenue reached 19.584 billion yuan, a year-on-year increase of 52.45%[5] - The company's pharmaceutical total agency brand promotion business sales revenue reached 10.696 billion yuan, a year-on-year increase of 60.82%[5] - The company's medical device total agency brand promotion business sales revenue reached 8.888 billion yuan, a year-on-year increase of 31.44%[5] - Total agency brand promotion business revenue grew 46.01% in 2023, with a 52.45% increase in gross profit[30] - Pharmaceutical new retail business revenue increased by 10.95% in 2023[30] - Digital logistics technology and supply chain solutions revenue grew 28.45% in 2023, with a 49.44% increase in gross profit[30] - Total agency brand promotion business revenue reached 19.584 billion yuan, a year-on-year increase of 46.01%[40] - Pharmaceutical new retail business revenue increased by 10.95% year-on-year[40] - Digital logistics technology and supply chain solutions revenue increased by 28.45% year-on-year[40] - Total agency brand promotion business (CSO) achieved sales revenue of 19.584 billion yuan, a year-on-year increase of 46.01%, with a gross profit of 2.789 billion yuan, up 52.45% year-on-year[43] - Pharmaceutical total agency brand promotion business achieved sales revenue of 10.696 billion yuan, a year-on-year increase of 60.82%, with a gross profit of 2.267 billion yuan, up 54.83% year-on-year[43] - Medical device total agency brand promotion business achieved sales revenue of 8.888 billion yuan, a year-on-year increase of 31.44%, with a gross profit of 522 million yuan, up 42.91% year-on-year[44] - Pharmaceutical industry self-production and OEM business achieved sales revenue of 2.476 billion yuan, with a gross profit margin of 23.84% and a gross profit of 590 million yuan[45] - JiuXin Traditional Chinese Medicine Group achieved self-production sales revenue of 1.2 billion yuan, with a gross profit margin of 25.6% and a gross profit of 307 million yuan[46] - Beijing Jingfeng Pharmaceutical Group achieved revenue of 466 million yuan, with 150+ products in production and 8 drugs passing consistency evaluation[46] - The company introduced 98 new high-quality products, including 2 with sales exceeding 100 million yuan and 10 with sales exceeding 10 million yuan[43] - The company completed the upgrade of the "Quanqing Health" brand and implemented the full-case brand upgrade for Kefei[43] - The company focused on developing large surgical, cardiovascular intervention, and IVD national platform distribution businesses, optimizing logistics systems and digital platforms[44] - The company produced 36,234 batches of traceable herbal pieces, with a total annual output of 8,991.44 tons, achieving full traceability in the herbal medicine supply chain[46] - Product sales revenue reached 1.882 billion yuan, with Jiuxin Traditional Chinese Medicine focusing on high-quality and safe products, offering a wide range of categories including precious herbs, fine drinks, and formula drinks[47] - The company has obtained 10 MAH Class II product registration certificates and 25 Class I product filing certificates, with 173 OEM medical device specifications and 424 drug OEM specifications, enhancing product competitiveness through self-developed and OEM products[47] - The "Wan Dian Jia Meng" (10,000 Store Franchise) plan has achieved significant progress, with 21,192 direct and franchise pharmacies by the end of Q1 2024, covering 31 provinces and 293 cities, and a target of over 30,000 stores by 2025[49] - Franchise pharmacy sales revenue reached 3.48 billion yuan, an 83.25% year-on-year increase, with 3,900 professional pharmacies, dual-channel pharmacies, and hospital-side stores, including 3.3 billion yuan in prescription outflow revenue[49] - B2C e-commerce total agency and sales business achieved 1.215 billion yuan in revenue, a 26.8% year-on-year growth, with rapid expansion on new e-commerce platforms like Douyin and Kuaishou[50] - The company's B2B e-commerce terminal sales channel generated 17.326 billion yuan in revenue, with the Yaojiujiu B2B platform achieving 11.241 billion yuan in self-operated transactions and covering 99% of administrative regions[51] - Retail e-commerce platform business revenue reached 6.085 billion yuan, an 11.47% year-on-year increase, with sales to JD.com and Alibaba's self-operated platforms exceeding 4.24 billion yuan, a 16.69% increase[52] - The company's logistics Bb/BC integrated warehousing and distribution system supports efficient supply chain logistics, enabling "zero inventory" for online and offline customers and sharing 100,000 product specifications[52] - The company has completed the "Bb/BC integrated warehousing and distribution" logistics service system, covering 6 "BC integrated warehouses" in Hubei, Shanghai, Guangdong, Beijing, Tianjin, and Zhejiang, and has upgraded 24 logistics centers to "Bb integrated" operations across 24 provinces[53] - The "Bb integrated project" was recognized as a leading case in digital transformation by the China Listed Companies Association and the "2023 Digital Economy Development Typical Case" by the Securities Daily[53] - The company launched the "New Medical" strategy, targeting the 321,000 clinics/outpatient departments in China, aiming to provide integrated supply chain and operational services to enhance terminal control[56] - The internet medical business achieved revenue of 156 million yuan in the reporting period, with 31 target hospitals connected to the prescription transfer platform[57] - The company is advancing the REITs project, planning to use 3.3 million square meters of pharmaceutical logistics assets as underlying assets, with the first batch of assets being the Wuhan logistics center, covering 172,000 square meters[59] - The company's digital transformation strategy has established a comprehensive digital platform, including ERP, logistics, and financial systems, supporting multiple business scenarios such as retail, new medical, and pharmaceutical distribution[61] - The company's financial shared cloud platform and "Bb integrated project" were selected as digital transformation典型案例 by the China Listed Companies Association in 2022 and 2023, respectively[61] - The company's "Bb/BC integrated warehousing and distribution project" was recognized as a "2023 Digital Economy Development Typical Case" by the Securities Daily[61] - The company's digital transformation projects, including the orthopedic smart service platform and retail digital operation platform, have been optimized and implemented[61] - The company aims to transition from a traditional pharmaceutical commercial enterprise to a technology-driven platform service provider through digital transformation[61] - The company's revenue from hospital markets reached 54.139 billion yuan, a year-on-year increase of 11.32%, with 268,600 medical institutions covered[62] - Revenue from tiered hospitals was 38.751 billion yuan, up 9.41% year-on-year, covering over 80% of tiered hospitals nationwide[62] - Revenue from primary medical institutions was 7.425 billion yuan, a year-on-year increase of 21.33%, covering over 60% of community health centers and township hospitals[63] - Revenue from private medical institutions was 7.963 billion yuan, up 12.19% year-on-year, serving major private medical groups[63] - The medical device segment achieved sales revenue of 32.815 billion yuan, a year-on-year increase of 11.66%, with 247,500 product specifications[63] - The company's orthopedic Chang'e intelligent service platform was completed, enhancing data service capabilities in the medical device field[64] - The traditional Chinese medicine (TCM) segment achieved sales revenue of 4.2 billion yuan, a year-on-year increase of 14.02%, with a gross profit of 776 million yuan[65] - The TCM segment covers 31 provinces and has established over 30 TCM production bases, with 40 varieties on the quality traceability platform[65] - The company partnered with leading domestic and foreign pharmaceutical companies, including Huarun Sanjiu, Yangtze River Pharmaceutical, and Novo Nordisk, to provide full-chain digital services[66] - Collaborations with medical device companies such as Mindray, MicroPort, and Philips enabled rapid supply to terminal markets through B2B/B2C/O2O platforms[66] - The company signed a strategic cooperation agreement with Johnson & Johnson, covering surgical, orthopedic, and interventional solutions, with a total value of nearly $500 million[67] - The company's logistics system for the "i Maotai" digital marketing platform achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million[68] - The company's logistics subsidiary, Jiuzhou Logistics, was recognized as one of Maotai Group's 23 strategic suppliers, standing out from over 2,000 suppliers[68] - The company's BC integrated warehouse in Hangzhou achieved a peak daily order volume of 216,000 and a peak monthly order volume of 1.91 million, while the Tianjin warehouse achieved a peak daily order volume of 20,000 and a peak monthly order volume of 350,000[68] - The company's logistics subsidiary, Jiuzhou Cloud Intelligence, completed a large-scale modern high-end intelligent pharmaceutical warehousing and logistics center project for Shandong Yiyang Health Group[69] - The company signed a memorandum of cooperation with Vietnam Airlines Logistics and Vietnam International Service and Trade Investment to collaborate on logistics information technology and supply chain solutions[70] - The company held the "2023 Jiuzhoutong Financial Institutions Seminar," inviting 32 major financial institutions to discuss future cooperation directions, including expanding credit lines and innovating credit products[71] - The company formed a joint venture, Hubei Jiuzhou Pharmaceutical Supply Chain Co., Ltd., to promote the development of the pharmaceutical supply chain industry in Hubei Province[73] - The company signed a strategic cooperation agreement with Tencent Health to upgrade digital management services, financial payment services, and business intelligence services[74] - The company established a joint artificial intelligence laboratory with Peking University Wuhan Artificial Intelligence Research Institute to enhance digital management and intelligent supply chain systems[74] - The company donated a total of over 3.4 million yuan to support education in 2023, including the construction of the Egret Kindergarten in Ulanhot, Inner Mongolia[75] - The company's 2022 ESG report was rated "A" by Wind ESG and ranked 2nd in the pharmaceutical business category in the 2023 Huazheng ESG rating[75] - The company donated automatic external defibrillators worth over 180,000 yuan to the Red Cross Society of Yingcheng City, Hubei Province, installed in 12 public places with high foot traffic[75] - The company actively participated in disaster relief efforts, organizing donations for the July 2023 floods in Beijing-Tianjin-Hebei and the December 2023 earthquake in Gansu[75] - The company was awarded the "Charitable Donation Enterprise" honor at the first Hubei Charity Awards in September 2023[75] - The "Opinions of the CPC Central Committee and the State Council on Promoting the Development and Growth of the Private Economy" (31 measures) was issued in July 2023, providing strong policy support for private enterprises like the company[76] - In November 2023, eight government departments jointly issued the "Notice on Strengthening Financial Support Measures to Promote the Development and Growth of the Private Economy", proposing 25 specific measures to support private enterprises[79] - The company, as a leading private enterprise in the pharmaceutical distribution industry, will benefit from the financial support policies, which will reduce financing costs and expand financing channels[80] - By 2025, the national and provincial centralized drug procurement is expected to cover more than 500 varieties[81] - The company's sales revenue in public hospitals has achieved a compound annual growth rate of 10.58% over the past three years, with the number of effective customers rapidly increasing to 13,800[85] - Over 70% of the company's existing business is in pharmacies and third-tier markets, benefiting from the outflow of hospital prescriptions and the flow of chronic disease medications to third-tier markets[85] - The company has actively promoted real-world data research on innovative drugs in private hospitals, fostering collaboration opportunities with innovative drug companies[85] - The "dual-channel" policy has been implemented nationwide, covering 2,612 drugs, with reimbursement ratios mostly ranging from 70% to 80%[88] - The company has expanded its business coverage in public hospitals, significantly benefiting from the centralized procurement policy[85] - The company has leveraged its supply chain advantages to secure distribution rights for centralized procurement products and opportunities for total agency promotion in the out-of-hospital market[86] - The company has been actively promoting the development of innovative drugs in private hospitals, enhancing collaboration with innovative drug companies[85] - The company has seen steady growth in sales scale in private hospitals through improved logistics management and supply chain services[85] - The company has capitalized on the expansion of the retail market due to the "dual-channel" and "outpatient coordination" policies[87] - The company has benefited from the dynamic adjustment of the number of drugs included in the "dual-channel" management, with the minimum number being 169 and the maximum being 529[88] - The number of "dual-channel" pharmacies in Shandong Province is expected to exceed 700 by the end of September 2023, with a fund payment ratio of around 70% and no less than 85% for primary medical institutions[89] - By the end of Q1 2024, the company has expanded its directly operated and franchised pharmacies to 21,192, with 3,900 specialty pharmacies, dual-channel pharmacies, and hospital-adjacent stores (including franchised stores)[91] - The company's Good Pharmacist pharmacies in Wuhan have been included in outpatient统筹 management, benefiting from policies such as "outpatient统筹," "dual-channel," and "seven unifications"[91] - The "clinic filing system" was implemented nationwide in 2023, leading to a potential rapid increase in the number of clinics in China[92] - The number of clinics in China reached 321,000 by the end of 2022, with 59,848 new clinics registered in the past year, a 75% increase year-on-year[93] - The clinic medication market in China is growing at a double-digit rate annually, with a market size approaching 200 billion yuan[93] - Jiuzhou Tong's "New Medical" strategy focuses on building a "Digital Medical + Supply Chain" industrial service platform targeting clinic customers, leveraging its strong supply chain capabilities and advanced information management systems[94] - The strategy includes a smart clinic solution combining auxiliary diagnosis systems, ERP systems, patient management systems, and doctor management systems to improve clinic operational efficiency[94] - Jiuzhou Tong aims to provide a turnkey solution for new clinics and drive business growth by integrating upstream supplier resources in specialized fields such as dentistry, medical aesthetics, and traditional Chinese medicine[94] - China's infrastructure REITs market has seen a series of supportive policies since the pilot program was officially launched in April 2020[95][96] - Key policy milestones include the "Guidelines for Public Offering of Infrastructure Securities Investment Funds (Trial)" in August 2020 and the "14th Five-Year Plan" in March 2021, which emphasized the healthy development of infrastructure REITs[97] - The "Notice on Further Improving the Pilot Work of Infrastructure REITs" in July 2021 highlighted the importance of project quality and long-term healthy development of infrastructure REITs[97] - In January 2022, the Ministry of Finance and the State Taxation Administration introduced tax incentives for REITs, allowing deferred taxation on asset transactions or equity acquisitions during the establishment phase[97] - The "Opinions on Further Revitalizing Existing Assets and Expanding Effective Investment" in May 2022 identified key areas for revitalizing existing assets, including infrastructure projects with large scale, good current returns, or growth potential[97] - The "Outline of the Strategic Plan for Expanding Domestic Demand (2022-2035)" in December 2022 proposed the orderly development of infrastructure REITs to form a virtuous cycle between existing assets and new investments[98] - The total scale of infrastructure REITs in China reached 115.6 billion yuan, including 110.5 billion yuan from initial projects and 5.1 billion yuan from expansion projects[101] - The company has approximately 3.3 million square meters of pharmaceutical logistics storage assets and supporting facilities available for REITs issuance[102] - The Chinese government has introduced multiple policies to support the development of REITs, including expanding the scale of REITs issuance and encouraging private investment[99][100][101] - The company's REITs issuance is expected to provide significant equity-based funding, supporting rapid business development[102] - The Chinese government has issued policies to promote the high-quality development of the REITs market,
九州通:九州通致投资者的一封信(2023年度)
2024-04-26 09:28
(2023 年度) 九州通医药集团股份有限公司 致投资者的一封信 敬启者: 春和景明,万物竞生。"高质量发展"是今年两会的热门词,以新质生产力更好地推动 高质量发展已成为社会的普遍共识。过去的一年,是中国改革开放 45 周年,是国内经济疫 后重生的第一年,也是公司持续贯彻高质量发展理念取得丰硕成果的一年。 在诸多变局不确定的大背景下,公司坚持高质量发展理念,不再片面追求销售收入规 模的扩张,注重经营管理质量的提升,经营性利润、经营性现金流、应收账款期限、资金 周转率和财务费用等各项指标均取得了良好的表现,公司的发展更加稳健、更加健康、更 加可持续。 过去的一年,我们全力拓展高质量业务,盈利能力不断提升。公司营业收入再创历史 新高,达到 1,501.40 亿元,较上年同期增长 6.92%;扣非归母净利润达 19.60 亿元,较上年 同期增长 13.06%,扣非归母净利润的增长快于营业收入的增长;经营活动现金流再创新 高,全年净额达 47.48 亿元,较上年同期增长 19.10%。在行业的支付环境没有明显改善的 情况下,公司的应收账款周转天数为 63 天,比上年缩短 6 天;公司资金周转天数为 80 天, 比上年 ...
九州通:九州通关于2023年度关联交易执行情况和2024年度关联交易预计的公告
2024-04-26 09:28
证券代码:600998 证券简称:九州通 公告编号:临 2024-023 九州通医药集团股份有限公司关于 公司召开第六届董事会独立董事专门会议第一次会议对上述关联交易预计 情况进行了审核,独立董事认为:公司的关联交易遵守了平等互利的市场交易原 则,定价公平合理,不存在损害公司股东尤其是中小股东利益的情形,不会对公 司持续经营能力及独立性造成影响,符合公司和股东的长远利益。 本事项尚需提交股东大会审议批准,楚昌投资集团有限公司及其一致行动人 上海弘康实业投资有限公司、中山广银投资有限公司、北京点金投资有限公司、 刘树林、刘兆年为关联股东将回避表决。 (二)前次关联交易的预计和执行情况 2023 年度关联交易执行情况和 2024 年度关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 本次关联交易事项尚需提交股东大会审议。 公司与关联方之间的关联交易,属于正常经营往来,以市场价格为基础 协商定价,不会影响公司的独立性,不会对公司的持续经营能力产生影响。 一、关联交易基本情况 (一)关联交易履行的审议 ...
九州通:九州通募集资金管理办法(2024年4月修订)
2024-04-26 09:28
九州通医药集团股份有限公司 募集资金管理办法 (2024年4月修订) 第一章 总则 第一条 为了规范九州通医药集团股份有限公司(以下简称"公司")募集资 金的使用与管理,提高募集资金使用效益,保护投资者的合法权益,根据《中华 人民共和国公司法》、《中华人民共和国证券法》、《首次公开发行股票并上市管理 办法》、《上市公司证券发行管理办法》、《关于前次募集资金使用情况报告的规 定》、《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》、 《上海证券交易所股票上市规则》和《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律、法规和规范性文件的规定,结合公司实际情况,特 制定《九州通医药集团股份有限公司募集资金管理办法》(以下简称"本办法")。 第二条 本办法所称募集资金是指公司通过公开发行证券(包括首次公开发 行股票、配股、增发、发行可转换公司债券、发行分离交易的可转换公司债券等) 以及非公开发行证券向投资者募集的资金,但不包括公司实施股权激励计划募集 的资金。 第三条 公司董事会应建立募集资金存储、使用和管理的内部控制制度,对 募集资金存储、使用、变更、监督和责任追究等内容进行明确规 ...
九州通:九州通第六届监事会第三次会议决议公告
2024-04-26 09:28
证券代码:600998 证券简称:九州通 公告编号:临 2024-022 九州通医药集团股份有限公司 第六届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 2024 年 4 月 25 日,九州通医药集团股份有限公司(以下简称"九州通"或"公 司")召开第六届监事会第三次会议,本次会议以现场方式召开,根据公司《监 事会议事规则》的相关规定,会议通知于 2024 年 4 月 14 日以电话、邮件、微信 等方式通知全体监事。本次会议应到监事 3 人,实到 3 人,会议由监事会主席许 应政先生主持。本次会议的召集和召开程序符合《公司法》及《公司章程》等相 关规定。 经过审议并表决,本次会议通过了以下议案: 1、2023 年年初母公司未分配利润 6,313,776,291.36 元,加上 2023 年度母公 司实现净利润 2,662,758,837.89 元,提取 10%法定公积金 266,275,883.80 元、对 股东分配 1,069,334,720.50 元,期末未分配利润为 7,640,924,524 ...
九州通:九州通医药集团股份有限公司2023年度独立董事述职报告(曾湘泉)
2024-04-26 09:28
九州通医药集团股份有限公司 2023年度独立董事述职报告(曾湘泉) 2023 年度,作为九州通医药集团股份有限公司(以下简称:公司)的独立 董事,我严格按照《公司法》《上市公司治理准则》《上海证券交易所股票上市规 则》《上市公司独立董事管理办法》及《公司章程》《独立董事制度》的规定,忠 实履行职责,积极出席公司历次董事会、股东大会和董事会专门委员会会议,认 真审议各项议案,对重要事项发表独立意见,运用各自的专业知识,为公司的科 学决策和规范运作提出意见和建议,充分发挥了独立董事对公司的监督、建议等 作用,切实维护了公司和全体股东的合法权益。现将本人在 2023 年度履行独立 董事职责的情况汇报如下: 一、独立董事的基本情况 (一)本人工作履历、专业背景以及兼职情况 作为公司的独立董事,本人拥有专业资质及能力,在从事的专业领域积累了 丰富的经验。本人工作履历、专业背景以及兼职情况如下: 本人曾湘泉, 69 岁,中国国籍,无境外居留权,经济学博士。长期从事劳 动经济和人力资源管理领域的教学和研究,在《经济研究》《中国社会科学》等 学术期刊发表多篇论文,2013 年被评为"长江学者"特聘教授。曾任中国人民 大学劳动 ...
九州通:九州通股东会议事规则(2024年4月修订)
2024-04-26 09:28
九州通医药集团股份有限公司 股东会议事规则 第一章 总则 第一条 为维护全体股东的合法权益,规范公司股东会的召开和表决程序,保 证股东会依法行使职权,根据《公司法》《上市公司股东大会规则》《上市公司治理 准则》等法律、行政法规、部门规章、规范性文件及《公司章程》的规定,制定本 规则。 第二条 公司董事会应当切实履行职责,认真、按时召集、组织股东会。公司 全体董事应当勤勉尽责,确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。 年度股东会每年召开一次,应当于上一会计年度结束后的六个月内举行。 临时股东会不定期召开,出现《公司法》第一百一十三条规定的应当召开临时 股东会的情形时,临时股东会应当在两个月内召开。 公司在上述期限内不能召开股东会的,应当报告公司所在地中国证券监督管理 委员会(以下简称"中国证监会")派出机构和上海证券交易所(以下简称"上交 所"),说明原因并公告。 第五条 公司召开股东会,应当聘请律师对以下问题出具法律意见并公告: (一)会议的召集、召开程序是否符合法律、行政法规、《公司章程》的规定; (二 ...
九州通:九州通监事会议事规则(2024年4月修订)
2024-04-26 09:28
九州通医药集团股份有限公司 监事会议事规则 第一条 宗旨 为进一步规范公司监事会的议事方式和表决程序,促使监事和监事会有效地 履行监督职责,根据《公司法》《证券法》以及《公司章程》和其他有关规定, 制定本规则。 第二条 监事会的组成 公司设监事会。监事会由 3 名监事组成,监事会设主席 1 人,可以设副主席。 监事会主席和副主席由全体监事过半数选举产生。 监事会应当包括股东代表和适当比例的公司职工代表,其中职工代表的比例 不低于 1/3。监事会中的职工代表由公司职工通过职工代表大会、职工大会或者 其他形式民主选举产生。 第三条 监事会的职权 监事会依据《公司法》《公司章程》以及有关法规行使下列职权: 1 (一)应当对董事会编制的公司定期报告进行审核并提出书面审核意见; (二)检查公司财务; (三)对董事、高级管理人员执行职务的行为进行监督,对违反法律、行政 法规、本章程或者股东会决议的董事、高级管理人员提出解任的建议; (四)当董事、高级管理人员的行为损害公司的利益时,要求董事、高级管 理人员予以纠正; (五)提议召开临时股东会,在董事会不履行《公司法》规定的召集和主持 股东会职责时召集和主持股东会; (六) ...
九州通:九州通对外投资管理制度(2024年4月修订)
2024-04-26 09:28
九州通医药集团股份有限公司 对外投资管理制度 (2024 年 4 月修订) 第二条 本制度所称对外投资是指公司以盈利或保值增值为目的的投资活 动,包括但不限于以下投资行为: (一)股权投资(新设企业、增资扩股及股权收购); (二)公司经营性项目及资产投资; (三)股票、基金、债券及其他证券投资; (四)金融机构委托理财(不包括保本型委托理财); (五)法律、法规规定的其他投资行为。 第三条 本制度适用于公司以及公司的全资子公司、控股子公司。本制度旨 在建立有效的控制机制,对公司及控股公司在组织资源、资产、投资等经营运作 过程中进行风险控制,保障资金运营的安全性和收益性,提高公司的抗风险能力。 第四条 公司的对外投资应遵循下列原则: (一)遵循国家法律、法规的规定; 第一章 总则 第一条 为了加强九州通医药集团股份有限公司(以下简称"公司")对外 投资的管理,防范对外投资风险,保障对外投资安全,提高对外投资效益,维护 投资者的利益,根据《公司法》《上海证券交易所股票上市规则》等法律、法规 和规范性文件以及《公司章程》的有关规定,结合公司实际情况,特制定本制度。 第六条 公司对外投资事项达到下列标准之一的,应当由 ...
九州通:九州通医药集团股份有限公司2023年度内部控制评价报告
2024-04-26 09:28
根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求(以下简称企业内部 控制规范体系),结合九州通医药集团股份有限公司(以下简称:公司)内部控制制度和评价办法,在 内部控制日常监督和专项监督的基础上,我们对公司2023年12月31日(内部控制评价报告基准日)的内 部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定,建立健全和有效实施内部控制,评价其有效性,并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏,并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整,提 高经营效率和效果,促进实现发展战略。由于内部控制存在的固有局限性,故仅能为实现上述目标提供 合理保证。此外,由于情况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低, 根据内部控制评价结果推测未来内部控制的有效性具有一定的 ...